COVID-19 Mortality in the Colorado Center for Personalized Medicine Biobank

Area of Science:

• Genomics and Precision Medicine
• Epidemiology
• Public Health

Background:

• COVID-19 has caused millions of deaths globally, yet specific mortality risk factors require further investigation.
• The Colorado Center for Personalized Medicine (CCPM) Biobank offers a valuable resource for studying disease outcomes using integrated health data.

Purpose of the Study:

• To identify and describe risk factors associated with COVID-19 mortality within the CCPM Biobank population.
• To analyze the association between pre-existing health conditions and COVID-19-related death.

Main Methods:

• Utilized integrated data from Electronic Health Records (EHRs) and the CCPM Biobank.
• Calculated cause-specific mortality and case-fatality rates for COVID-19.
• Performed multivariable logistic regression to assess the impact of pre-existing conditions (defined by phecodes) on COVID-19 mortality.

Main Results:

• Out of 155,859 participants, 20,797 contracted COVID-19, and 190 deaths were attributed to the virus.
• The COVID-19 case-fatality rate was 0.91%, with a mortality rate of 122 per 100,000 persons.
• Significant risk factors for COVID-19 mortality included older age, male sex, hypertensive chronic kidney disease (OR: 10.14), and type 2 diabetes with renal manifestations (OR: 5.59).

Conclusions:

• Older males with pre-existing kidney conditions are at a substantially elevated risk of COVID-19 mortality.
• These findings highlight the need for specialized care strategies for high-risk patient groups.
• Personalized medicine approaches can leverage integrated data to identify and mitigate COVID-19 mortality risks.